Phase I/II study of VELCADE [bortezomib]-BEAM [carmustine + cytarabine + etoposide + melphalan] and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin's lymphoma, transformed or mantle cell lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 02 Aug 2018
At a glance
- Drugs Bortezomib (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan
- Indications Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 12 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 01 Jun 2012 Planned end date changed from 1 Jan 2012 to 1 Jan 2015 as reported by ClinicalTrials.gov.
- 06 May 2011 Planned End Date changed from 1 Jan 2010 to 1 Jan 2012 as reported by ClinicalTrials.gov.